Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

10/22/2019, Tuesday

Media Contacts:
Kristy Marks
Kristy.marks@bausch.com
(908) 927-0683

Alli Cloutier
alli.cloutier@zenogroup.com
(212) 299-8956

 

BAUSCH + LOMB TO PRESENT NEW DATA DURING THE AMERICAN ACADEMY OF OPTOMETRY MEETING IN ORLANDO

Eye Care Professionals Invited to Attend Educational Events, Learn about Company’s Latest Product Innovations at Booth #801

BRIDGEWATER, N.J., Oct. 22, 2019 – Bausch + Lomb, a leading global eye health company, today announced that six new scientific poster and clinical presentations involving the company’s products, as well as data from the company’s Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the Annual Meeting of the American Academy of Optometry (AAO) in Orlando, Fla. (Oct. 23-27, 2019).

Eye care professionals are also invited to attend educational events and learn more about the company’s latest product innovations, including the Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, Ocuvite® Eye Performance vitamins and PreserVision® AREDS 2 Formula minigel eye vitamins, as well as the expansion of parameters for Biotrue® ONEday daily disposable lenses, at the company’s booth #801.

“We look forward to an eventful AAO this year, where attendees can learn more about these new data, visit the Bausch + Lomb booth to explore some of the latest innovations from our comprehensive product portfolio and hear first-hand about the benefits our products can provide patients during our educational events,” said Joe Gordon, U.S. president, Bausch + Lomb.

Scientific Poster and Presentations
The full schedule of posters and presentations that will feature Bausch + Lomb’s innovations include:

Clinical Presentations
  • DeCory H et al. “Real-world Persistence with Latanoprostene Bunod Ophthalmic Solution 0.024%: Analysis of Patient Longitudinal Data.” W224 ABC, Orange County Convention Center, Friday, Oct. 25 at 2:00 p.m. ET.
Scientific Posters
  • Cavet M et al. “Loteprednol Etabonate (Submicron) 0.38% Gel for the Reduction of Inflammation and Pain following Cataract Surgery: Integrated Analysis of Three Phase 3 Studies.” Poster #42, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24 from 4:30 to 6:30 p.m. ET.
  • Rah M et al. “Identifying Opportunities for Contact Lens Wear Through Challenges Experienced by Presbyopic Astigmatic Patients Wearing Spectacles.” Poster #50, Exhibit Hall WD1, Orange County Convention Center, Friday, Oct. 25 from 9:00 a.m. to 3:00 p.m. ET.
  • Reindel WT et al. “Progressive Multifocal Contact Lenses for the Astigmatic Presbyope: A Comparison of Power Profiles Across Near, Intermediate and Distance Zones.” Poster #51, Exhibit Hall WD1, Orange County Convention Center, Friday, Oct. 25 from 9:00 a.m. to 3:00 p.m. ET.
  • Sanfilippo C et al. “Antibiotic Resistance Rates Among Bacterial Pathogens Collected from the Cornea in ARMOR.” Poster #54, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24 from 4:30 to 6:30 p.m. ET.
  • Sanfilippo C et al. “Antibiotic Resistance Trends Among Ocular Pathogens in the United States: Ten-Year Results from the ARMOR Study.” Poster #55, Exhibit Hall WD1, Orange County Convention Center, Thursday, Oct. 24 from 4:30 to 6:30 p.m. ET.

Educational Events
Wednesday, Oct. 23
AAO attendees are invited to attend “Industry Innovations Lunch & Learn” at the Rosen Plaza Hotel (9700 International Dr, Orlando, Fla.), Grand Ballroom D, Level 1, from 11:50 a.m. to 12:50 p.m. Art Epstein, O.D., and Ben Gaddie, O.D., will lead a clinical discussion of everyday challenging patient cases featuring products from the company’s Vision Care, Consumer Health Care and Pharmaceuticals portfolio, including Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, LUMIFY® redness reliever eye drops, LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% and ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension).

Thursday, Oct. 24
Jason Jedlicka, O.D., will lead a discussion on “Finding the Right Fit with Zenlens™ and Zen™ RC scleral lenses” during a Vision Theater lecture session from 1:00 to 1:30 p.m. at the Orange County Convention Center (9800 International Blvd., Orlando, Fla.), Exhibit Hall D2 & E1 in Theater 1.

Friday, Oct. 25
During a Vision Theater Lecture session, “Making Sense of Ocular Nutrition,” Jeffry Gerson, O.D., will discuss the AREDS studies and nutrients essential to eye health. The program will be held from 11:00 to 11:30 a.m. at the Orange County Convention Center (9800 International Blvd., Orlando, Fla.), Exhibit Hall, Theater 1.

Featured Bausch + Lomb Products
Throughout the meeting, eye care professionals can learn more about some of the company’s latest product innovations at the company’s booth #801. This includes Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional’s fit set. This monthly silicone hydrogel lens combines the company’s unique 3-Zone Progressive™ multifocal design with the stability of its OpticAlign® toric design, providing the estimated 32 million people in the U.S. living with both astigmatism and presbyopia an advanced contact lens technology that offers maximized wearing comfort, exceptional visual clarity and the convenience of same-day fitting during the initial lens exam.

Attendees can also find out more about the company’s flagship daily disposable contact lens brand, Biotrue® ONEday, which is the fastest growing family of daily disposable lenses in the United States. Earlier this month, Bausch + Lomb announced it was expanding the parameters for Biotrue® ONEday lenses (six new parameters). (The full release can be found at http://bit.ly/BiotrueONEdayParameterExpansion).

The company’s new Ocuvite® Eye Performance vitamins and PreserVision® AREDS 2 Formula minigel eye vitamins will also be featured in the booth. Ocuvite® Eye Performance vitamins were formulated with seven vital nutrients that help strengthen the macula, which helps protect the eye from stressors such as sun light and blue light emitted from digital devices. PreserVision® AREDS 2 minigels have replaced the currently offered PreserVision® AREDS 2 Formula soft gels, providing patients a new, smaller-sized pill than the current soft gel. For more information on Ocuvite® Eye Performance and PreserVision® AREDS 2 minigels, visit www.bausch.com/newsroom.

Other innovations from the Bausch + Lomb Vision Care, Consumer Health Care and Pharmaceuticals divisions will also be featured.

Important Safety Information for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%

INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation.
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please see full prescribing information at www.bausch.com/vyzulta

Important Safety Information for LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

INDICATION
LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

IMPORTANT SAFETY INFORMATION

  • LOTEMAX® SM, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation.
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infections.
  • Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal cultures should be taken when appropriate.
  • Contact lenses should not be worn when the eyes are inflamed.
  • There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information for LOTEMAX® SM.

Important Safety Information for BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%

INDICATION
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*

*Efficacy for this organism was studied in fewer than 10 infections.

IMPORTANT SAFETY INFORMATION

  • BESIVANCE® is not for injection into the eye.
  • As with other anti-infectives, prolonged use of BESIVANCE® may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
  • Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE®.
  • The most common adverse event reported in approximately 2% of patients treated with BESIVANCE® was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
  • Safety and effectiveness in infants below one year of age have not been established.

Click here for full Prescribing Information for BESIVANCE®.

Important Safety Information for ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension)

INDICATION
ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) is used to treat certain inflammatory eye conditions that have either a bacterial infection or a risk of bacterial infection. ZYLET® contains two types of medicines. One is an anti-inflammatory and the other is an anti-bacterial medicine.

IMPORTANT SAFETY INFORMATION

  • Do not use ZYLET® if you have eye infections caused by: most types of viruses; bacteria known as mycobacteria; or fungus.
  • ZYLET® contains a medicine known as a corticosteroid. Using corticosteroids for a long period of time may result in glaucoma and impaired vision. If you use ZYLET® for 10 days or longer, your doctor may monitor pressure in your eye.
  • Use of corticosteroids may result in cataract formation.
  • Use of steroids (corticosteroids) after cataract surgery may delay healing and increase bleb formation (a type of lesion on the eye).
  • Use of corticosteroids may increase the chance, or the severity, of an infection in your eye, or it may hide an eye infection. If your eye symptoms do not improve after 2 days of taking ZYLET®, contact your doctor for an examination.
  • The most common adverse reactions were eye redness, superficial punctate keratitis (a specific type of eye surface irritation), increased pressure in the eye, and burning and stinging when putting ZYLET® drops in the eye.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information forZYLET®.

About Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see better. Its core businesses include over-the-counter products, dietary supplements, eyecare products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.  

###

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS).
Any other product/brand names are trademarks of the respective owners.
© 2019 Bausch & Lomb Incorporated or its affiliates.
MTB.0479.USA.19

Print

Number of views (1374)/Comments (0)

x